One and a half decades ago, variants (G1 and G2) in the apolipoprotein L1 (APOL1; G0) gene were reported with an excess risk of Focal Segmental Sclerosis (FSGS), HIV-Associated Nephropathy (HIVAN), and other forms of CKD and ESKD in AAAs [2,3,4]. This evidence concerns the gene APOL1 and chronic kidney disease.